Clinical Trial

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

Withdrawn Phase 1/2
View on ClinicalTrials.gov →
Why the trial stopped
The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio.
Summary
RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-27; most recent amendment 2026-06-23.
Status change: Not Yet Recruiting → Withdrawn 2026-06-23
Trial Details
NCT Number NCT07006805
Lead Sponsor Cabaletta Bio
Conditions Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis (MS) - Relapsing-remitting, Progressive Multiple Sclerosis
Start Date 2026-06
Primary Completion 2028-09 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-25